

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup>:</b> <b>A61K 9/51</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/30620</b> <b>(43) International Publication Date:</b> 2 June 2000 (02.06.00)
<b>(21) International Application Number:</b> PCT/EP99/09072 <b>(22) International Filing Date:</b> 24 November 1999 (24.11.99)  <b>(30) Priority Data:</b> MI98A002557 25 November 1998 (25.11.98) IT  <b>(71)(72) Applicant and Inventor:</b> GASCO, Maria, Rosa [IT/IT]; Lungo Po Antonelli, 207, I-10153 Torino (IT).  <b>(74) Agent:</b> GERVASI, Gemma; Notarbartolo & Gervasi, Corso di Porta Vittoria, 9, I-20122 Milan (IT).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> SOLID LIPIDIC NANOSPHERES SUITABLE TO A FAST INTERNALIZATION INTO CELLS  <b>(57) Abstract</b>  The present invention relates to pharmaceutical compositions in form of solid lipidic nanospheres able to fast penetrate into the cells, comprising as an active substance a lipidic substance consisting of an ester of $\alpha$ -tocopherol or $\delta$ -tocopherol or of cholesterol or of glycerol with a carboxylic acid selected from acetic acid, propionic acid, butyric acid and succinic acid, useful in the treatment of tumoral pathologies and of Mediterranean anaemia.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# SOLID LIPIDIC NANOSPHERES SUITABLE TO A FAST INTERNALIZATION INTO CELLS

## FIELD OF THE INVENTION

The present invention relates to pharmaceutical compositions in form of solid lipidic nanospheres able to fast penetrate into the cells, the process for their preparation and their use in the treatment of tumoral pathologies and of Mediterranean anaemia.

## PRIOR ART

It is known from literature that the carboxylic acids having a low number of carbon atoms, such as acetic acid, propionic acid, butyric acid and succinic acid, and their derivatives, may inhibit the proliferation of the tumoral cells, in particular in the case of colon cancers (H.P. Scheppach, F. Ritcher, Eur. J. Cancer Prevention, 4, 373-378, 1995, and 31, 1077-1080, 1995).

There are in particular experimental proofs showing the antiproliferative activity of the butyric acid salts, for example of the sodium salt, towards a great variety of neoplastic cells (S.P. Landon et al., Cancer res., 48, 6161-6165, 1988; D. Coradini et al., Cell Prolif., 30, 149-159, 1997; H. Yamamoto et al., Int. J. Cancer, 76, 897-902, 1998). Recent studies showed that sodium butyrate is able to modulate the expression of the oncogenes and of the genes regulating the apoptosis in cells from different histotypes (O.C. Velasquez et al., J. Parenteral Enteral Nutr., 20, 243-250, 1996; M. Mandal, R. Kumar, Cell Growth Diff., 7, 311-318, 1996).

It is moreover known that the carboxylic acids themselves and/or certain derivatives thereof may help in a significant way, in the case of the Mediterranean anaemia, the transformation of  $\beta$ -globin to  $\gamma$ -globin, or fetal globin, resulting in an improvement of the disease (S. P. Perine et al., New England J. Medicine, 328, 81-86, 1993; A.F. Collins et al., Blood, 85, 43-49, 1995).

At present, the use of such compounds is however strongly limited by the difficulty in reaching effective plasmatic concentrations, owing to the short half-life time, which makes the metabolism and the excretion of said substances too fast. In order to obtain satisfactory results therefore one ought to administrate high amounts of acid, with the drawback of causing harmful side effects.

Therefore one feels the need to have an adequate system of release for these substances, which allows to decrease their doses, thus minimising the side effects.

### SUMMARY

- 5 Now the Applicant found new pharmaceutical compositions allowing to overcome the drawbacks of the prior art, showing a surprisingly high biological activity.

Said pharmaceutical compositions are prepared in form of solid lipidic nanospheres characterised in that they include as an active substance a lipidic substance consisting of an ester of  $\alpha$ -tocopherol or  $\delta$ -tocopherol or of cholesterol  
10 or of glycerol with a carboxylic acid selected from the group consisting of acetic acid, propionic acid, butyric acid and succinic acid, and if necessary one or more further pharmacologically active substances.

A further object of the present invention is the process for the preparation of said lipidic nanospheres, comprising the following steps:

- 15 a) heating of a mixture comprising a lipidic substance and one or more surfactants at a temperature such as to take the mixture to melting;  
b) heating of a mixture consisting of water and one or more co-surfactants at a temperature at least equal to the step a) one;  
c) hot mixing under mild stirring of the mixture of the step b) with the mixture of the  
20 step a), with the achievement of a microemulsion;  
d) dispersion of the microemulsion obtained in the step c) in pre-cooled water;  
e) washing of the dispersion of the step d) with distilled water by diafiltration;  
f) freeze-drying of the product obtained in the step e) or its hot sterilisation,

characterised in that said lipidic substance consists of an ester of  $\alpha$ -tocopherol or  
25  $\delta$ -tocopherol or of cholesterol or of glycerol with a carboxylic acid selected from the group consisting of acetic acid, propionic acid, butyric acid and succinic acid.

The pharmaceutical compositions in form of solid lipidic nanospheres object of the present invention are useful in the treatment of all the pathological conditions for which the administration of the above mentioned carboxylic acids is effective, and  
30 they are particularly suitable for the treatment of tumoral pathologies and of the Mediterranean anaemia.

The characteristics and the advantages of the solid lipidic nanospheres as a release system for the carboxylic acids according to the present invention and of the related preparation process will be pointed out in detail in the following description.

5 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to pharmaceutical compositions in form of solid lipidic nanospheres obtained from microemulsions of a lipidic substance, stabilised by at least a surfactant and by one or more cosurfactants.

10 With the term lipidic nanospheres in the present invention we mean particles having an average diameter lower than 300 nm.

For the preparation of said microemulsions a lipidic substance in a mixture with one or more surfactants, and if necessary one or more further pharmacologically active substances, is heated to melting; separately a mixture consisting of water and one or more cosurfactants is heated to a temperature at least equal to that  
15 one at which the mixture containing the lipidic substance melts. The aqueous mixture is then hot added under mild stirring to the mixture containing the lipidic substance, obtaining a microemulsion.

The so obtained microemulsion is poured into precooled water at a temperature ranging from 2 to 10 °C under mild stirring, using a water amount ranging from  
20 10:1 to 80:1 parts by volume with respect to the volume of the microemulsion. The so obtained dispersion is then washed many times with distilled water by diafiltration in order to remove the components soluble in water, using a TCF2 equipment (Amicon-Grace-Danvers, USA) equipped with a YM 100 Diaflo membrane with a 100,000 Dalton cut-off, as disclosed in R. Cavalli et al., S. T. P. Pharma Sciences, 2(6), 514-518, 1992.  
25

Such dispersion is finally hot sterilised in autoclave at 121 °C for 15 minutes at 2 atm, or freeze-dried.

The so obtained lipidic nanospheres have an average diameter ranging from 40 to 300 nm, and preferably from 100 to 200 nm, and a polydispersion index ranging  
30 from 0.10 to 0.50.

The characterisation of the microemulsions has been carried out by

photocorrelation spectroscopy with a N 4 Coulter instrument, as disclosed in R. Cavalli et al., Int. J. Pharm., 148, 47-54, 1997.

The lipidic substance used in the preparation of the lipidic nanospheres according to the present invention is selected from the group consisting of esters of  
5 cholesterol or  $\alpha$ -tocopherol or  $\delta$ -tocopherol or glycerol with carboxylic acids having a low number of carbon atoms, selected from the group consisting of acetic acid, propionic acid, butyric acid and succinic acid.

Said lipidic substance constitutes the essential active substance of the lipidic nanospheres, which however may include, in particular embodiment forms of the  
10 present invention, one or more other pharmacologically active substances.

Such further active substances are typically selected from the group consisting of doxorubicin, idarubicin and taxol.

According to a preferred embodiment form of the present invention said lipidic substance is cholesteryl butyrate.

15 As surfactants phosphatidylcholine taken from soy or egg yolk, phospholipids and their mixtures are typically used.

According to a preferred embodiment form of the present invention the used surfactant is a commercial product known with the name Epikuron 200® (Lukas Meyer, Hamburg, Germany), consisting of phosphatidylcholine for 95%.

20 The cosurfactants are selected from alcohols, such as butyl alcohol, carboxylic acids such as butyric and hexanoic acid and bile salts such as sodium taurocholate and sodium glycocholate.

According to a preferred embodiment form of the present invention, in the preparation of the microemulsion the various substances are used in the following  
25 proportions, expressed as percentages by weight with respect to the total weight of the microemulsion:

- |                      |        |
|----------------------|--------|
| - lipidic substance: | 5-18%  |
| - surfactants:       | 10-20% |
| - cosurfactants:     | 12-18% |
| 30 - water:          | 44-70% |

In the preferred embodiment form the lipidic nanospheres obtained by diafiltration

have a titre in lipidic substance ranging from 25 to 42%, the residue consisting of phosphatidylcholine and/or phospholipids and by traces of other substances used in the preparation process.

According to a particularly preferred embodiment form of the present invention the composition of the solid lipidic nanospheres, expressed as percentage by weight of the various components, is the following one:

- cholesteryl butyrate 31.5%
- phosphatidylcholine 68.0%
- other 0.5%

10 Owing to their small size and their composition, said nanospheres have the unexpected characteristic to be rapidly internalised into cells, where the active substance is fast released.

With respect to the systems of the prior art, said solid lipidic nanospheres therefore are the ideal release system for active substances such as the low molecular weight carboxylic acids present in the esters of the present invention. In fact they allow a strong reduction of the effective doses, with subsequent limitation of the side effects.

15 The pharmaceutical compositions in form of solid lipidic nanospheres of the present invention may therefore be successfully used in the treatment of all the pathologies for which the above mentioned characteristics of fast internalisation of the active substance into the cells are important.

The pharmaceutical compositions in form of lipidic nanospheres object of the present invention are useful in the treatment of all the pathologies for which the administration of acetic acid, propionic acid, butyric acid and succinic acid is effective, and in particular in the treatment of the tumoral pathologies and of Mediterranean anaemia.

25 For said uses the nanospheres according to the invention may be used alone, or in a mixture with pharmacologically acceptable excipients and/or diluents, and/or pharmacologically active substances. In particular embodiment forms of the pharmaceutical compositions according to the present invention, said active substances are antineoplastic agents.

The following examples of preparation of pharmaceutical compositions in form of solid lipidic nanospheres are reported for illustrative, but not limitative purpose of the present invention.

#### EXAMPLE 1

- 5 a) 15 mg of Epikuron 200® (95% phosphatidylcholine) and 1 mg of phosphatidylinositol are added to 9 mg of cholesteryl butyrate, and such a mixture is heated to melting at about 75 °C;
- b) a mixture consisting of water (62 mg), sodium glycocholate (3 mg) and butyl alcohol (10 mg) is heated at the same temperature of the mixture of the step a);
- 10 c) under mild stirring and at the same temperature of the preceding steps, the mixture of the step b) is added to the mixture of the step a), obtaining a microemulsion, which turns out to be clear;
- d) the microemulsion obtained in the step c) is dispersed in water precooled at 5 °C in an amount equal to 20 parts by volume of water for each part of
- 15 microemulsion, obtaining a dispersion of nanospheres;
- e) the dispersion obtained in the step d) is washed for 2 times with distilled water by diafiltration;
- f) the washed dispersion is finally freeze-dried.

By photocorrelation spectroscopy the average diameter of the nanospheres has

20 been determined, which turned out to be equal to 120 nm, with a polydispersion index equal to 0.25.

The so obtained nanospheres consist for 35.5% of cholesteryl butyrate and for 64% of phosphatidylcholine.

#### EXAMPLE 2

- 25 a) 16 mg of Epikuron 200® (95% phosphatidylcholine) are added to 7 mg of cholesteryl butyrate and heated to the melting of the mixture at about 77 °C;
- b) at the same temperature of the step a) a mixture consisting of water (62 mg), sodium taurocholate (3 mg) and butyl alcohol (12 mg) is heated;
- c) the mixture of the step b) is added, under mild stirring and always at the same
- 30 temperature of the previous steps, to the mixture of the step a), obtaining a clear microemulsion;



d) the microemulsion obtained in the step c) is dispersed in water precooled at 2 °C in an amount equal to 40 parts by volume of water for each part of microemulsion, obtaining a dispersion of nanospheres;

5 e) the dispersion obtained in the step d) is washed for 3 times with distilled water by diafiltration;

f) the washed dispersion is finally sterilised according to FU IX at 121 °C and at the pressure of 2 atmospheres.

The average diameter of the nanoparticles, determined by photocorrelation spectrometry, turned out to be 150 nm, with a polydispersion index equal to 0.35.

10 The so obtained nanospheres consist of 30% cholesteryl butyrate, and of 69% phosphatidylcholine.

#### TESTS OF INHIBITION OF THE CELL PROLIFERATION

The experimentation has been carried out on NIH-H460 cells of lung carcinoma (D.N. Carney et al., Cancer Res., 45, 2913-2923, 1985) grown in monolayer in the  
15 RPMI 1640 nutrient medium (Bio Whittaker, Verviers, Belgium) added with 10% by volume with respect to the total volume of FCS (Fetal Calf Serum), at the temperature of 37 °C, in a CO<sub>2</sub> atmosphere humidified at 5%.

The cells have been put in 24 wells plates, using as nutrient medium RPMI 1640 added with 10% of FCS, and left to adhere for 24 hours. The insemination medium  
20 has been then removed and substituted with the experimental medium consisting of RPMI 1640 with 10% of FCS and increasing concentrations of sodium butyrate, or of cholesteryl butyrate in form of nanospheres prepared as in the above reported example 1. The cells have been kept for 6 days in contact with such experimental medium.

25 The effect of the sodium butyrate and of cholesteryl butyrate on the cell growth has been estimated counting the cells by a Cell Counter.

Thus it has been observed that the nanospheres containing cholesteryl butyrate induced a complete inhibition of the cell growth, at a concentration equal to 0.21 mM of cholesteryl butyrate, while the sodium butyrate, at the same concentration,  
30 induced an inhibition of the cell growth limited to 50%.

Contemporaneously a comparison test has been carried out using cholesterol as

an additive of the experimental medium consisting of RPMI 1640 with 10% FCS, by which it has been observed that the cholesterol does not affect the cell proliferation in any way.

The above described experiment has been repeated on cells of the mastocarcinoma, identified with the MCF7 abbreviation, using as insemination medium DMEM/F12 (Dulbecco's modified Eagle's medium, Sigma Chemical Co., St. Louis, MO) with 2% FCS.

Said cells have been placed in 12 well plates, where they have been left to adhere for 24 hours in the above described nutrition medium.

The nutrient medium has been then removed and substituted with the experimental medium consisting of DMEM/F12 with 10% FCS added with increasing concentrations of sodium butyrate, or of cholesteryl butyrate in form of nanospheres prepared according to the above reported example 2. The cells have been kept for 6 days in contact with such experimental medium.

The antiproliferative effect of the cholesteryl butyrate nanospheres on the cell growth has been estimated counting the cells with a Cell Counter. From such measurements turned out that the nanospheres containing cholesteryl butyrate induced a complete inhibition of the cell growth at a concentration equal to 0.2 mM of cholesteryl butyrate, while the sodium butyrate induced, at the same concentration, an inhibition of cell growth limited to 40%.

#### TESTS ON THE INTERNALIZATION IN THE CELLS

The internalisation of the nanospheres containing cholesteryl butyrate in cells of the lung carcinoma, identified with the NIH-H460 abbreviation, has been studied by observation at the fluorescence microscope.

Operating according to the above reported example 1 nanospheres containing cholesteryl butyrate have been prepared, which have been made fluorescent by addition of cumarin 6.

NIH-H460 cells, added with 50  $\mu$ l of tagged nanospheres, have been incubated at 37 °C, and samples have been taken in different times to be examined.

Said samples have been washed with a saline solution buffered with phosphate buffer, centrifuged and added with a solution containing 5  $\mu$ g/ml of propidium

iodide.

The so treated cells have been observed and photographed by fluorescence microscope in parallel with the control consisting of the same cells added with propidium iodide only.

- 5 It has been observed that, contrary to the control, the cells treated with the nanospheres made fluorescent by cumarin 6 containing cholesteryl butyrate appeared almost totally fluorescent already after 5 minutes from the treatment, demonstrating an almost complete internalisation of the nanospheres in the cells in very short times.

CLAIMS

1. Pharmaceutical composition in the form of solid lipidic nanospheres, characterised in that said nanospheres comprise as an active substance a lipidic substance consisting of an ester of  $\alpha$ -tocopherol or  $\delta$ -tocopherol or of cholesterol  
5 or of glycerol with a carboxylic acid selected from the group consisting of acetic acid, propionic acid, butyric acid and succinic acid.
2. Pharmaceutical composition as claimed in claim 1, characterised in that said lipidic substance is cholesteryl butyrate.
3. Pharmaceutical composition as claimed in claim 1, characterised in that said  
10 nanospheres have an average diameter lower than 300 nm and a polydispersion index ranging from 0.10 to 0.50.
4. Pharmaceutical composition as claimed in claim 3, characterised in that the average diameter of the nanospheres is ranging from 100 to 200 nm.
5. Pharmaceutical composition as claimed in claim 1, characterised in that the  
15 amount of the active lipidic substance in the nanospheres is ranging from 25 to 42% by weight, the residue being constituted by phosphatidylcholine and/or phospholipids.
6. Pharmaceutical composition as claimed in claim 1, characterised in that it comprises one or more further active substances selected from the group  
20 consisting of taxol, idarubicin and doxorubicin.
7. Process for the preparation of solid lipidic nanospheres as defined in claim 1, comprising the following steps:
  - a) heating of a mixture comprising a lipidic substance and one or more surfactants at a temperature such as to take the mixture to the melting;
  - 25 b) heating of a mixture consisting of water and one or more co-surfactants at a temperature equal to the step a) one;
  - c) mixing under mild stirring of the mixture disclosed in the step b) with the mixture of the step a), with the achievement of a microemulsion;
  - d) dispersion of the microemulsion obtained in the step c) in precooled water;
  - 30 e) washing of the dispersion of the step d) with distilled water by diafiltration;
  - f) freeze-drying or sterilising of the product obtained in the step e),

characterised in that said lipidic substance consists of an ester of  $\alpha$ -tocopherol or  $\delta$ -tocopherol or of cholesterol or of glycerol with a carboxylic acid selected from the group consisting of acetic acid, propionic acid, butyric acid and succinic acid.

8. Process as claimed in claim 7, characterised in that said lipidic substance is cholesteryl butyrate.

9. Process as claimed in claim 7, characterised in that said surfactant of the step a) is selected from the group consisting of soy phosphatidylcholine, egg phosphatidylcholine, phospholipids and their mixtures.

10. Process as claimed in claim 7, characterised in that the mixture of the step a) further includes one or more active substances selected from taxol, idarubicin and doxorubicin.

11. Process as claimed in claim 7, characterised in that said co-surfactant at the step b) is selected from the group consisting of butanol, butyric acid, hexanoic acid, sodium taurocholate and sodium glycocholate.

12. Process as claimed in claim 7, characterised in that said lipidic substance is present in said microemulsion of the step c) in an amount ranging from 5 to 18% by weight with respect to the total weight.

13. Process as claimed in claim 7, characterised in that the amount of water in the mixture of the step b) is ranging from 44 to 70% by weight with respect to the total weight of the microemulsion.

14. Process as claimed in claim 7, characterised in that the amount of surfactants present in the mixture at the step a) is ranging from 10 to 20% by weight with respect to the total weight of the microemulsion.

15. Process as claimed in claim 7, characterised in that the amount of co-surfactants present in the aqueous mixture at the step b) is ranging from 12 to 18% by weight with respect to the total weight of the microemulsion.

16. Process as claimed in claim 7, characterised in that said dispersion of the step d) is carried out with water cooled to 2-10 °C in an amount ranging from 10:1 to 80:1 parts by volume with respect to the volume of the mixture of the step c).

17. Process as claimed in claim 7, characterised in that at the step f) solid lipidic nanospheres are obtained having an average diameter lower than 300 nm and

polydispersion index ranging from 0.10 to 0.50.

18. Use of a lipidic substance consisting of an ester of  $\alpha$ -tocopherol or  $\delta$ -tocopherol or of cholesterol or of glycerol with a carboxylic acid selected from the group consisting of acetic acid, propionic acid, butyric acid and succinic acid, as  
5 an active substance for the preparation of a pharmaceutical composition in form of solid lipidic nanospheres.

19. Use as claimed in claim 18, characterised in that said lipidic substance is cholesteryl butyrate.

20. Use as claimed in claim 18, characterised in that said pharmaceutical  
10 composition is useful in the treatments based on the administration of acetic acid, propionic acid, butyric acid and succinic acid.

21. Use as claimed in claim 18, characterised in that said pharmaceutical composition is useful in the treatment of the tumoral pathologies and of the Mediterranean anaemia.

22. Use as claimed in claim 18, characterised in that said nanospheres may be  
15 administered alone, or in mixture with pharmacologically acceptable excipients and/or diluents, and/or with pharmacologically active substances.

23. Use as claimed in claim 22, characterised in that said pharmacologically active substances are antineoplastic agents.

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/09072

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/51

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X Y	WO 98 56362 A (GASCO MARIA ROSA) 17 December 1998 (1998-12-17) page 2, line 5 -page 4, line 21  page 7; examples 1,2 claims 1-3	1-5, 18-23 7-9, 11-13, 17
Y A	WO 94 20072 A (PHARMACIA AB ;WESTESEN KIRSTEN (DE); SIEKMANN BRITTA (DE)) 15 September 1994 (1994-09-15) abstract page 13, line 19 -page 19, line 12 page 25; example 1 page 26; example 2 page 41; example 23 claims 1,3,4,8,11,16,17,19,26  -/-	7-9, 11-13, 17  6,10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (see specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search

28 March 2000

Date of mailing of the international search report

04/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,  
Fax (+31-70) 340-9018

Authorized officer

Muller, S

# INTERNATIONAL SEARCH REPORT

Intern. Application No  
PCT/EP 99/09072

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EP 0 526 666 A (GASCO MARIA ROSA)  10 February 1993 (1993-02-10)  abstract  column 2, line 32 -column 4, line 4  column 4; example 1  claims 1-15</p>	1,3



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/EP 99/09072

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9856362 A	17-12-1998	IT MI971385 A AU 7915898 A	14-12-1998 30-12-1998
WO 9420072 A	15-09-1994	CA 2091152 A AU 676279 B AU 6225394 A EP 0687172 A FI 954143 A JP 8507515 T NO 953461 A NZ 262541 A US 5785976 A US 5885486 A	06-09-1994 06-03-1997 26-09-1994 20-12-1995 19-10-1995 13-08-1996 06-11-1995 24-04-1997 28-07-1994 23-03-1999
EP 0526666 A	10-02-1993	AT 136774 T DE 69118880 D DE 69118880 T ES 2089066 T US 5250236 A	15-05-1996 23-05-1996 07-11-1996 01-10-1996 05-10-1993